
Nelfinavir was removed from the PBS[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. on 1 December 2008, due largely to it's high dosing schedule and the fact that there are other PIs which perform as well if not better,
| Generic name: | nelfinavir (NFV) |
|---|---|
| Pronunciation: | nel-FIN-aveer |
| Brand name: | Viracept |
| Also known as: | AG1343 Generic versions include Nelvir, Nelfin, Nelvex and Nefavir. |
| Drug class: | protease inhibitor |
| Availability in Australia: |
|
| Presentation: | 250mg tablets; 625mg tablets; 50mg/g oral powder |
| Links: |
|
Like all anti-HIV drugs, nelfinavir must be taken in combination with other drugs to be completely effective. Commonly, nelfinavir is combined with two nucleoside (NRTI) drugs, although other combinations are sometimes used. Your doctor will advise you on the right combination of drugs to suit your circumstances.
The normal adult dose is either 3 x 250mg tablets 3 times a day or 2 x 625mg tablets twice a day.
Regardless of what you read on this website or elsewhere, you should always take your medications according to your doctor's instructions. If you're unsure, speak to your doctor or pharmacist.
Nelfinavir should be taken with food.
All drugs can produce side effects in some people. These may be mild, moderate or severe, so you should be aware of potential side effects before starting any drug, and speak to your doctor if you experience side effects that concern you.
It's unlikely you will experience all of these side effects, and you may not experience any side effects at all. Before starting any new drug, ask your doctor about side effects you might experience and discuss strategies for dealing with side effects if they do occur. If you experience any significant side effect you should continue taking your medicine and see your doctor as soon as possible.
| Attachment | Size |
|---|---|
| ppi_viracept.pdf | 36.82 KB |